Betting on NK cell therapy, Intellia and ONK reached a cooperation of more than 900 million US dollars to develop CRISPR gene editing cancer cell therapy

Written | Edited by Wang Cong | Typeset by Wang Duoyu | Shui Chengwen Recently, Intellia Therapeutics, a CRISPR gene editing company founded by Nobel Prize winner Jennifer Doudna, is trading like crazy - investing in SparingVision, an eye disease gene therapy company, and participating in the creation of a universal CAR-T cell therapy company , acquisition of new gene editing technology company Rewrite Therapeutics, cooperation with ONK Therapeutics to develop CRISPR gene editing NK cell therapy and so on
.

On February 3, 2022, Intellia Therapeutics announced the acquisition of Rewrite Therapeutics, a previously unknown novel gene editing technology company, for $200 million to expand its gene editing tools and R&D pipeline
.

On February 15, 2022, less than two weeks after the last transaction, Intellia Therapeutics announced a partnership of up to $920 million with ONK Therapeutics
.

Intellia will grant ONK a non-exclusive patent license for its in vitro gene editing and LNP delivery technologies, as well as an exclusive patent license for certain gRNAs, for the development of five CRISPR gene-edited allogeneic NK cell therapies for which ONK is clinically responsible In pre- and clinical development, Intellia will receive up to $184 million in R&D and milestone payments per cell therapy, as well as 50% royalties on future product sales, and Intellia will also be entitled to up to two CRISPR gene-edited NK cells Worldwide co-development and co-commercialization rights for the therapy
.

This is also Intellia's second bet on cancer cell therapy after participating in the creation of a general-purpose CAR-T cell therapy company in June 2021 (completed in partnership with Blackstone and Cellex)
.

Intellia Therapeutics Intellia Therapeutics, founded by Nobel Prize winner Jennifer Doudna, is currently the most valuable CRISPR gene editing company (about $7.
2 billion)
.

In June 2021, Intellia published a paper in the New England Journal of Medicine [1], showing that its CRISPR gene editing therapy NTLA-2001 was safe and effective in clinical trials for the treatment of transthyretin amyloidosis (ATTR).
This is also the result of the world's first clinical trial of an in vivo CRISPR gene editing therapy, proving that CRISPR gene editing can be precisely performed in vivo to treat genetic diseases through a single intravenous infusion of the CRISPR gene editing system
.

The paper has attracted worldwide attention since its publication, and is regarded as opening a new era of medicine
.

NTLA-2001 Therapeutic Principle Intellia R&D Pipeline ONK Therapeutics ONK Therapeutics, a NK cell therapy startup, just completed a $21.
5 million Series A financing last month
.

Committed to developing the next generation of off-the-shelf, general-purpose, genetically engineered NK cell therapy for the treatment of hematological malignancies and solid tumors
.

ONK R&D pipeline as well as CISH gene knockout cord blood-derived NK cell therapy and CISH gene knockout iPSC-derived NK cell therapy
.

Reference link: https:// -and-onk-therapeutics-announce-collaboration-advance "Bioworld" recently launched a "NK cell" column, which interprets and introduces the latest research progress and reviews in the field of NK cells every week, as well as related startup company reports and interviews
.

We have also established a professional NK cell exchange group, long press the QR code below, add the editor-in-chief WeChat, and note the unit-research direction/position-name
.

Open reprint welcome to forward to Moments and WeChat groups